Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

For the last 20 years, integrins have been a therapeutic target of interest in the treatment of fibrotic diseases, particularly regarding the integrins of the αV family. Initially developed as anti-cancer drugs but with modest benefits, inhibitors of integrins (such as the anti-αV cilengitide) have shown interesting anti-fibrotic effects in different organs including the heart. Cardiac fibrosis is defined as an accumulation of stiff extracellular matrix in the myocardium, and ultimately leads to heart failure, one of the leading causes of mortality worldwide. Understanding the determinants of cardiac fibrosis and the involvement of integrins is a major matter of public health. This review presents the current knowledge on the different types of cardiac fibrosis and their etiologies, and report on first data supporting specific integrin inhibition therapy as a novel anti-fibrotic strategy, in particular to treat cardiac fibrosis. © 2022 médecine/sciences – Inserm.


Clément Delacroix, Jean-Sébastien Hulot. Integrins in cardiac fibrosis]. Medecine sciences : M/S. 2022 May;38(5):438-444

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35608466

View Full Text